The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Seroxat     (3S,4R)-3-(benzo[1,3]dioxol- 5-yloxymethyl)...

Synonyms: Frosinor, Motivan, Oxetine, Aropax, paroxetine, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Aropax


Psychiatry related information on Aropax

  • CONCLUSIONS: Paroxetine is an effective treatment for patients with generalized social phobia [6].
  • CONCLUSIONS: Paroxetine showed moderate benefit for depressive symptoms and mental health function in elderly patients with dysthymia and more severely impaired elderly patients with minor depression [7].
  • INTERVENTIONS: Patients were randomly assigned to receive paroxetine (n = 137) or placebo (n = 140), starting at 10 mg/d and titrated to a maximum of 40 mg/d, or problem-solving treatment-primary care (PST-PC; n = 138) [7].
  • For dysthymia, paroxetine improved mental health functioning vs placebo among patients whose baseline functioning was high (difference in mean [SE] change in SF-36 mental component scores, 5.8 [2.02]; P =. 01) or intermediate (difference in mean [SE] change in SF-36 mental component scores, 4.4 [1.74]; P =.03) [7].
  • Adult night terrors and paroxetine [8].

High impact information on Aropax


Chemical compound and disease context of Aropax


Biological context of Aropax


Anatomical context of Aropax

  • Levels of mRNA for the SERT in the raphe nucleus were also unaltered by chronic paroxetine treatment [23].
  • The determination of the binding parameters of 3H-paroxetine revealed that, in rats treated for 21 d with paroxetine (10 mg/kg/d, s.c.), following a 48 hr washout Kd values were unchanged but Bmax values were reduced by 70% and 60% in hippocampal and cortical membranes, respectively [24].
  • RNA-injected Xenopus oocytes accumulate 5HT, and paroxetine or desipramine inhibit this uptake [25].
  • Chronic administration of selective serotonin reuptake inhibitor (SSRI) paroxetine modulates human motor cortex excitability in healthy subjects [26].
  • Paroxetine in breast milk [27].

Associations of Aropax with other chemical compounds


Gene context of Aropax


Analytical, diagnostic and therapeutic context of Aropax

  • METHODS: In a double-blind study of 40 patients with malignant melanoma who were eligible for high-dose interferon alfa therapy, we randomly assigned 20 patients to receive the antidepressant paroxetine and 20 to receive placebo [1].
  • METHODS: This was a placebo-controlled multicenter study comprising a single-blind acute treatment phase (12 weeks) and a randomized, double-blind maintenance treatment phase (24 weeks) for patients who had responded to paroxetine during the acute phase [35].
  • Compared with placebo, paroxetine treatment significantly (P<.001) improved the symptoms of social anxiety as shown on the Liebowitz Social Anxiety Scale, Social Phobia Inventory, Sheehan Disability Scale, Symptom Checklist-90 score, and EuroQol visual analogue scale, indicating decreased disability and increased well-being [35].
  • CONCLUSION: Paroxetine had no influence on fatigue in patients receiving chemotherapy [36].
  • In a double-blind, placebo controlled and crossover study, 19 subjects received daily 20 mg paroxetine or placebo, respectively, over a period of 30 days separated by a wash-out period of 3 months [37].


  1. Paroxetine for the prevention of depression induced by high-dose interferon alfa. Musselman, D.L., Lawson, D.H., Gumnick, J.F., Manatunga, A.K., Penna, S., Goodkin, R.S., Greiner, K., Nemeroff, C.B., Miller, A.H. N. Engl. J. Med. (2001) [Pubmed]
  2. Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial. Stearns, V., Beebe, K.L., Iyengar, M., Dube, E. JAMA (2003) [Pubmed]
  3. Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. Roose, S.P., Laghrissi-Thode, F., Kennedy, J.S., Nelson, J.C., Bigger, J.T., Pollock, B.G., Gaffney, A., Narayan, M., Finkel, M.S., McCafferty, J., Gergel, I. JAMA (1998) [Pubmed]
  4. The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome. Creed, F., Fernandes, L., Guthrie, E., Palmer, S., Ratcliffe, J., Read, N., Rigby, C., Thompson, D., Tomenson, B. Gastroenterology (2003) [Pubmed]
  5. Hyperglycemia associated with paroxetine. Petty, K.J. Ann. Intern. Med. (1996) [Pubmed]
  6. Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial. Stein, M.B., Liebowitz, M.R., Lydiard, R.B., Pitts, C.D., Bushnell, W., Gergel, I. JAMA (1998) [Pubmed]
  7. Treatment of dysthymia and minor depression in primary care: A randomized controlled trial in older adults. Williams, J.W., Barrett, J., Oxman, T., Frank, E., Katon, W., Sullivan, M., Cornell, J., Sengupta, A. JAMA (2000) [Pubmed]
  8. Adult night terrors and paroxetine. Wilson, S.J., Lillywhite, A.R., Potokar, J.P., Bell, C.J., Nutt, D.J. Lancet (1997) [Pubmed]
  9. Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care: a randomized trial. Kroenke, K., West, S.L., Swindle, R., Gilsenan, A., Eckert, G.J., Dolor, R., Stang, P., Zhou, X.H., Hays, R., Weinberger, M. JAMA (2001) [Pubmed]
  10. Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder. Liebowitz, M.R., Gelenberg, A.J., Munjack, D. Arch. Gen. Psychiatry (2005) [Pubmed]
  11. Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression. Murphy, G.M., Hollander, S.B., Rodrigues, H.E., Kremer, C., Schatzberg, A.F. Arch. Gen. Psychiatry (2004) [Pubmed]
  12. Modulation of cortical-limbic pathways in major depression: treatment-specific effects of cognitive behavior therapy. Goldapple, K., Segal, Z., Garson, C., Lau, M., Bieling, P., Kennedy, S., Mayberg, H. Arch. Gen. Psychiatry (2004) [Pubmed]
  13. Paroxetine retards disease onset and progression in Huntingtin mutant mice. Duan, W., Guo, Z., Jiang, H., Ladenheim, B., Xu, X., Cadet, J.L., Mattson, M.P. Ann. Neurol. (2004) [Pubmed]
  14. Selective serotonin reuptake inhibitor-induced sexual dysfunction: efficacy of a drug holiday. Rothschild, A.J. The American journal of psychiatry. (1995) [Pubmed]
  15. Pindolol potentiation of paroxetine for generalized social phobia: a double-blind, placebo-controlled, crossover study. Stein, M.B., Sareen, J., Hami, S., Chao, J. The American journal of psychiatry. (2001) [Pubmed]
  16. Inhibition of norepinephrine uptake in patients with major depression treated with paroxetine. Gilmor, M.L., Owens, M.J., Nemeroff, C.B. The American journal of psychiatry. (2002) [Pubmed]
  17. Double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression. Nemeroff, C.B., Evans, D.L., Gyulai, L., Sachs, G.S., Bowden, C.L., Gergel, I.P., Oakes, R., Pitts, C.D. The American journal of psychiatry. (2001) [Pubmed]
  18. Impulsive aggression in personality disorder correlates with tritiated paroxetine binding in the platelet. Coccaro, E.F., Kavoussi, R.J., Sheline, Y.I., Lish, J.D., Csernansky, J.G. Arch. Gen. Psychiatry (1996) [Pubmed]
  19. Platelet reactivity in depressed patients treated with paroxetine: preliminary findings. Musselman, D.L., Marzec, U.M., Manatunga, A., Penna, S., Reemsnyder, A., Knight, B.T., Baron, A., Hanson, S.R., Nemeroff, C.B. Arch. Gen. Psychiatry (2000) [Pubmed]
  20. Selective serotonin reuptake inhibitors directly signal for apoptosis in biopsy-like Burkitt lymphoma cells. Serafeim, A., Holder, M.J., Grafton, G., Chamba, A., Drayson, M.T., Luong, Q.T., Bunce, C.M., Gregory, C.D., Barnes, N.M., Gordon, J. Blood (2003) [Pubmed]
  21. Pharmacogenetics of antidepressant medication intolerance. Murphy, G.M., Kremer, C., Rodrigues, H.E., Schatzberg, A.F. The American journal of psychiatry. (2003) [Pubmed]
  22. Paroxetine in human breast milk and nursing infants. Stowe, Z.N., Cohen, L.S., Hostetter, A., Ritchie, J.C., Owens, M.J., Nemeroff, C.B. The American journal of psychiatry. (2000) [Pubmed]
  23. Effects of chronic antidepressant treatments on serotonin transporter function, density, and mRNA level. Benmansour, S., Cecchi, M., Morilak, D.A., Gerhardt, G.A., Javors, M.A., Gould, G.G., Frazer, A. J. Neurosci. (1999) [Pubmed]
  24. Desensitization of the neuronal 5-HT carrier following its long-term blockade. Piñeyro, G., Blier, P., Dennis, T., de Montigny, C. J. Neurosci. (1994) [Pubmed]
  25. Drosophila serotonin transporters have voltage-dependent uptake coupled to a serotonin-gated ion channel. Galli, A., Petersen, C.I., deBlaquiere, M., Blakely, R.D., DeFelice, L.J. J. Neurosci. (1997) [Pubmed]
  26. Chronic administration of selective serotonin reuptake inhibitor (SSRI) paroxetine modulates human motor cortex excitability in healthy subjects. Gerdelat-Mas, A., Loubinoux, I., Tombari, D., Rascol, O., Chollet, F., Simonetta-Moreau, M. Neuroimage (2005) [Pubmed]
  27. Paroxetine in breast milk. Wisner, K.L., Findling, R.L., Perel, J.M. The American journal of psychiatry. (2001) [Pubmed]
  28. Selective serotonin reuptake inhibitors directly alter activity of neurosteroidogenic enzymes. Griffin, L.D., Mellon, S.H. Proc. Natl. Acad. Sci. U.S.A. (1999) [Pubmed]
  29. Norepinephrine-deficient mice lack responses to antidepressant drugs, including selective serotonin reuptake inhibitors. Cryan, J.F., O'Leary, O.F., Jin, S.H., Friedland, J.C., Ouyang, M., Hirsch, B.R., Page, M.E., Dalvi, A., Thomas, S.A., Lucki, I. Proc. Natl. Acad. Sci. U.S.A. (2004) [Pubmed]
  30. Occupancy of serotonin transporters by paroxetine and citalopram during treatment of depression: a [(11)C]DASB PET imaging study. Meyer, J.H., Wilson, A.A., Ginovart, N., Goulding, V., Hussey, D., Hood, K., Houle, S. The American journal of psychiatry. (2001) [Pubmed]
  31. Paroxetine decreases platelet serotonin storage and platelet function in human beings. Hergovich, N., Aigner, M., Eichler, H.G., Entlicher, J., Drucker, C., Jilma, B. Clin. Pharmacol. Ther. (2000) [Pubmed]
  32. Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. Preskorn, S.H. Clinical pharmacokinetics. (1997) [Pubmed]
  33. Determinants of interindividual variability and extent of CYP2D6 and CYP1A2 inhibition by paroxetine and fluvoxamine in vivo. Ozdemir, V., Naranjo, C.A., Shulman, R.W., Herrmann, N., Sellers, E.M., Reed, K., Kalow, W. Journal of clinical psychopharmacology. (1998) [Pubmed]
  34. Breastfeeding during maternal antidepressant treatment with serotonin reuptake inhibitors: infant exposure, clinical symptoms, and cytochrome p450 genotypes. Berle, J.Ø., Steen, V.M., Aamo, T.O., Breilid, H., Zahlsen, K., Spigset, O. The Journal of clinical psychiatry. (2004) [Pubmed]
  35. Efficacy of paroxetine for relapse prevention in social anxiety disorder: a 24-week study. Stein, D.J., Versiani, M., Hair, T., Kumar, R. Arch. Gen. Psychiatry (2002) [Pubmed]
  36. Differential effects of paroxetine on fatigue and depression: a randomized, double-blind trial from the University of Rochester Cancer Center Community Clinical Oncology Program. Morrow, G.R., Hickok, J.T., Roscoe, J.A., Raubertas, R.F., Andrews, P.L., Flynn, P.J., Hynes, H.E., Banerjee, T.K., Kirshner, J.J., King, D.K. J. Clin. Oncol. (2003) [Pubmed]
  37. Modulation of behavior and cortical motor activity in healthy subjects by a chronic administration of a serotonin enhancer. Loubinoux, I., Tombari, D., Pariente, J., Gerdelat-Mas, A., Franceries, X., Cassol, E., Rascol, O., Pastor, J., Chollet, F. Neuroimage (2005) [Pubmed]
WikiGenes - Universities